Document is current

Article History

Received: 15 January 2023

Revised: 11 April 2023

Accepted: 17 April 2023

First Online: 27 April 2023

Competing interests

: MS receives industry research support from Amgen, Bristol-Myers Squibb/Celgene, Gilead, Janssen, Miltenyi Biotec, Morphosys, Novartis, Roche, Seattle Genetics, and Takeda, and serves as a consultant/advisor to AvenCell, CDR-Life, Ichnos Sciences, Incyte Biosciences, Janssen, Molecular Partners, and Takeda. She serves on the speakers’ bureau at Amgen, AstraZeneca, BMS/Celgene, Gilead, GSK, Janssen, Novartis, Pfizer, Roche, and Takeda. VB has received research funding from Miltenyi Biotec, Novartis, and Pfizer, and has served as a consultant/advisor to Novartis, Amgen, and Gilead. He serves on the speakers’ bureau at Novartis and Pfizer. AK (now employed by BioNTech SE) and JM (employed by Miltenyi Biotec) hold a patent on the AdCAR platform. CMS holds a patent on the AdCAR platform and has received research funding from Miltenyi Biotec. FE, UB, and SD are employed by Miltenyi Biotec. MvB has received research support from and serves on the speakers’ bureau at Gilead, Miltenyi Biotec, MSD Sharpe & Dohme, Roche, Mologen, Novartis, Astellas, and BMS. HL is co-founder and shareholder of Tubulis GmbH. DN, MSponheimer, DB, MK, TS, NP, LR, DA, KB (now employed by Bristol-Myers Squibb), and AL declare no relevant conflicts of interest.